Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance

– LINZESS® 2023 U.S. net sales of $1.1 billion, an increase of 7% year-over-year, driven by EUTRx prescription demand growth of 10% year-over-year –


– 2023 Ironwood revenue of $443 million,...

Related Keywords

Massachusetts ,United States ,Japan ,Canada ,Switzerland ,China ,Boston ,American ,America ,Tom Mccourt ,Drug Administration ,Linkedin ,Ironwood Pharmaceuticals Inc ,Pharmaceuticals Development Company Inc ,Exchange Commission ,Abbvie Inc ,Ironwood Pharmaceuticals Nasdaq ,Nasdaq ,Astrazeneca ,Ironwood Pharmaceuticals ,American Society For Pediatric Gastroenterology ,Full Year ,Brand Collaboration ,Lancet Gastroenterology ,American Society ,Pediatric Gastroenterology ,Annual Meeting ,United European Gastroenterology ,Host Disease ,Development Company ,Sales Growth ,Common Adverse Reactions ,Prescribing Information ,Boxed Warning ,Annual Report ,Quarterly Reports ,Consolidated Statements ,Markets ,